BILL SUMMARY
2nd Session of the 59th Legislature

Bill No.:	**HB 3574**
Version:	**FA1**
Request Number:	**10331**
Author:	**Rep. Pae**
Date:	**2/26/2024**
Impact:	**$0**

Research Analysis

The proposed floor amendment to HB3574, adds and modifies definitions of Kratom products, and prohibits vendors from preparing, distributing, selling, or displaying any kratom product containing more than one percent (1%) of 7-hydroxymitragynine in its alkaloid composition.

Kratom products may not exceed fifty milligrams of total alkaloids per serving and must meet residual solvent level standards outlined for pharmaceutical products by the Food and Drug Administration (FDA).

Kratom products are required to have a label on the product that links to a website, and sale or transfer to individuals under 18 years old is prohibited.

Product packaging must clearly state the amounts of total alkaloids, federal food allergen labeling requirements must be met, along with clear usage directions.

Liquid kratom products must have clear serving size markings. Powdered kratom products without capsules must include a calibrated measuring device in the packaging.

The measure further requires the inclusion of statements about product safety and effectiveness, and prohibits product labels from making therapeutic claims unless approved by the FDA.

Prepared By: Stefne Miller

Fiscal Analysis

HB 3574 modifies definitions pertaining to kratom products under the Oklahoma Kratom Consumer Protection Act. Kratom vendors are prohibited from selling products containing more than one percent (1%) of 7-hydroxmyitragynine in its alkaloid composition, contain more than fifty (50) milligrams of total alkaloids per serving, or contain levels of residual solvent from the manufacture that exceed the allowable amount for pharmaceutical products.

This measure requires Kratom vendors to disclose additional information on a product label, including the total kratom alkaloids contained in the product and packaging; directions for safe consumption; statements including product intent and warnings; and a statement prohibiting therapeutic claims unless approved by the United States Food and Drug Administration (FDA). The modifications required by this measure are not anticipated to directly impact the state budget or appropriations.

The floor amendment does not affect the fiscal impact of this measure.

Prepared By: Alexandra Ladner, House Fiscal Staff

Other Considerations

None.